Has Biotech Met Its Moment?

In this episode of Motley Fool Money, Tim Beyers and Karl Thiel discuss the biotech industry, focusing on recent VC funding increases and family office investments. While Karl expresses guarded optimism due to fluctuating quarterly data, they explore the potential opportunities for public market investors. They address the reasons for negativity surrounding biotech, including high interest rates and regulatory concerns, but highlight increased M&A activity as a positive sign. The conversation pivots to comparing Eli Lilly, a stable, large-cap company with successful weight loss drugs, to Viking Therapeutics, a smaller, riskier late-stage company with promising data in the same space. Ultimately, both hosts favor Viking for its potential for higher returns, acknowledging the greater risk involved, and touch on the history of the biotech industry, identifying Cetus Corp as potentially the first biotech company.